Corcept Therapeutics Incorporated (CORT) P/E Ratio History
ExpensiveTrading at 97.5x vs 5Y avg 42.0x · 90th percentile · Material premium to history · Data 2016–2026
Loading P/E history...
P/E Ratio Analysis
As of June 21, 2026, Corcept Therapeutics Incorporated (CORT) trades at a price-to-earnings ratio of 97.5x, with a stock price of $79.91 and trailing twelve-month earnings per share of $0.46.
The current P/E is 132% above its 5-year average of 42.0x. Over the past five years, CORT's P/E has ranged from a low of 22.2x to a high of 115.2x, placing the current valuation at the 90th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, CORT trades at a 341% premium to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, CORT commands a significant premium over the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CORT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CORT Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
CORT P/E vs Peers
Commercial Rare Disease Biopharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 6.8Lowest | 0.66Best | +817% | |
| $2B | 12.3 | - | +8% | |
| $1B | 26.8 | 3.58 | +1883%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
CORT Historical P/E Data (2016–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $40.31 | $0.35 | 115.2x | +121% |
| FY2025 Q4 | Dec 31 2025 | $34.80 | $0.82 | 42.4x | -19% |
| FY2025 Q3 | - | $83.11 | $0.88 | 94.4x | +81% |
| FY2025 Q2 | Jun 30 2025 | $73.40 | $1.13 | 65.0x | +25% |
| FY2025 Q1 | Mar 31 2025 | $114.22 | $1.16 | 98.5x | +89% |
| FY2024 Q4 | - | $50.39 | $1.24 | 40.6x | -22% |
| FY2024 Q3 | Sep 30 2024 | $46.28 | $1.26 | 36.7x | -30% |
| FY2024 Q2 | Jun 30 2024 | $32.49 | $1.13 | 28.8x | -45% |
| FY2024 Q1 | Mar 31 2024 | $25.19 | $1.06 | 23.8x | -54% |
| FY2023 Q4 | Dec 31 2023 | $32.48 | $0.95 | 34.2x | -34% |
| FY2023 Q3 | Sep 30 2023 | $27.25 | $0.81 | 33.6x | -35% |
| FY2023 Q2 | Jun 30 2023 | $22.25 | $0.83 | 26.8x | -49% |
| FY2023 Q1 | Mar 31 2023 | $21.66 | $0.82 | 26.4x | -49% |
| FY2022 Q4 | Dec 31 2022 | $20.31 | $0.88 | 23.1x | -56% |
| FY2022 Q3 | Sep 30 2022 | $25.64 | $1.00 | 25.6x | -51% |
| FY2022 Q2 | - | $23.78 | $0.94 | 25.3x | -51% |
| FY2022 Q1 | - | $22.52 | $0.91 | 24.7x | -53% |
| FY2021 Q4 | Dec 31 2021 | $19.80 | $0.89 | 22.2x | -57% |
| FY2021 Q3 | - | $19.68 | $0.83 | 23.7x | -55% |
| FY2021 Q2 | Jun 30 2021 | $22.00 | $0.76 | 28.9x | -44% |
| FY2021 Q1 | Mar 31 2021 | $23.79 | $0.78 | 30.5x | -41% |
| FY2020 Q4 | - | $26.16 | $0.85 | 30.8x | -41% |
| FY2020 Q3 | Sep 30 2020 | $17.41 | $0.89 | 19.6x | -62% |
| FY2020 Q2 | - | $16.82 | $0.94 | 17.9x | -66% |
| FY2020 Q1 | - | $11.89 | $0.88 | 13.5x | -74% |
| FY2019 Q4 | - | $12.10 | $0.78 | 15.5x | -70% |
| FY2019 Q3 | Sep 30 2019 | $14.13 | $0.72 | 19.6x | -62% |
| FY2019 Q2 | Jun 30 2019 | $11.15 | $0.64 | 17.4x | -67% |
| FY2019 Q1 | Mar 31 2019 | $11.74 | $0.61 | 19.2x | -63% |
| FY2018 Q4 | Dec 31 2018 | $13.36 | $0.60 | 22.3x | -57% |
| FY2018 Q3 | Sep 30 2018 | $14.02 | $1.19 | 11.8x | -77% |
| FY2018 Q2 | Jun 30 2018 | $15.72 | $1.16 | 13.6x | -74% |
| FY2018 Q1 | Mar 31 2018 | $16.45 | $1.12 | 14.7x | -72% |
| FY2017 Q4 | Dec 31 2017 | $18.06 | $1.02 | 17.7x | -66% |
| FY2017 Q3 | Sep 30 2017 | $19.30 | $0.29 | 66.4x | +27% |
| FY2017 Q2 | Jun 30 2017 | $11.80 | $0.20 | 58.8x | +13% |
| FY2017 Q1 | Mar 31 2017 | $10.96 | $0.11 | 100.4x | +93% |
| FY2016 Q4 | Dec 31 2016 | $7.26 | $0.07 | 105.2x | +102% |
| FY2016 Q3 | Sep 30 2016 | $6.50 | $0.04 | 175.7x | +237% |
| FY2016 Q2 | - | $5.46 | $0.01 | 474.8x | +811% |
Average P/E for displayed period: 52.1x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CORT — Frequently Asked Questions
Quick answers to the most common questions about buying CORT stock.
What is CORT's P/E ratio?
Corcept Therapeutics Incorporated (CORT) trailing twelve-month P/E ratio is 97.5x, based on TTM diluted EPS of $0.46. The 5-year average P/E is 42.0x and the historical range spans 22.2x to 115.2x.
Is CORT stock overvalued or undervalued?
CORT trades at 97.5x P/E, above its 5-year average of 42.0x. The 90th percentile ranking within the 22.2x–115.2x historical range indicates a premium to historical valuation.
Is CORT stock expensive?
Yes, CORT is expensive relative to its own history. The current P/E of 97.5x is above the 5-year average of 42.0x and also above the Healthcare sector median of 22.1x. The stock sits at the 90th percentile of its 5-year valuation range.
What is CORT's historical P/E range?
Over the past 5 years, CORT's P/E ratio has ranged from 22.2x to 115.2x, with a median of 28.9x and an average of 42.0x. The current P/E of 97.5x places the stock at the 90th percentile of this range. Full historical data spans 2016–2026.
How does CORT's P/E compare to the S&P 500?
CORT trades at 97.5x P/E versus the S&P 500 median of 24.4x. The 300% premium to the market typically reflects higher expected earnings growth or quality.
How does CORT's valuation compare to Healthcare peers?
Corcept Therapeutics Incorporated P/E of 97.5x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is CORT's PEG ratio?
CORT PEG ratio is N/A, based on a P/E of 97.5x and EPS growth of -33.3%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is CORT's earnings yield?
CORT earnings yield is 1.03%, the inverse of its 97.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.